Glucagon-like peptide-1 is a 30- or 31-amino-acid-long peptide hormone deriving from tissue-specific posttranslational processing of the proglucagon peptide.
Purpose: This study aims to investigate the possible impacts of fasting on physical activity and weight loss in adult users of glucagon-like peptide-1 (GLP-1) agonists, specifically semaglutide and tirzepatide, using qualitative methods to gain...
Gastrointestinal peptides Glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) are incretin hormones that are released after ingestion of a meal (figure 1). They stimulate glucose-dependent insulin release from the...
Wu F, Smith MR, Mueller AL, et al. Association of glucagon-like peptide receptor 1 agonist therapy with the presence of gastric contents in fasting patients undergoing endoscopy under anesthesia care: a historical cohort study.
Plasma glucagon-like peptide-1 (GLP-1) concentrations (A: total; B: intact, biologically active) during intravenous (blue) and subcutaneous (red) infusions of GLP-1 (736 amide) in fasting subjects with type 2 diabetes and hyperglycaemia.
Effects of glucagon-like peptide-1 (GLP-1)(7-36)amide on fasted and fed motility in the rat small intestine were investigated in relation to its dependence on nitric oxide (NO), insulin, and somatostatin.
The Relation Between Femoral Arterial Intima-Media Thickness and Fasting Serum Glucagon-Like Peptide-1.
The incretin glucagon-like peptide-1 (GLP-1), which is used to treat diabetes mellitus, delays gastric emptying by inhibiting vagal activity. GLP-1 also increases fasting and postprandial gastric volume in humans.
